Ten Capital Wealth Advisors’s ADMA Biologics ADMA Stock Holding History

Ten Capital Wealth Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200	Closed	-$662	–	203
2023 Q1	$662	Hold	200	–	–	﹤0.01%	493
2022 Q4	$776	Hold	200	–	–	﹤0.01%	499
2022 Q3	$0	Hold	200	–	–	﹤0.01%	550
2022 Q2	$0	Hold	200	–	–	﹤0.01%	457
2022 Q1	$0	Buy	+200	New	+$312	﹤0.01%	474

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ten Capital Wealth Advisors's ADMA Position: Q2 2023 in Review

Ten Capital Wealth Advisors sold out of ADMA Biologics (ADMA) in Q2 2023, closing a stake of 200 shares — an estimated $662 sold.

Ten Capital Wealth Advisors first reported a position in ADMA in Q1 2022 and held it in 5 quarters. The position peaked at $776 in Q4 2022. 179 funds tracked by Wall St. Rank hold ADMA as of Q2 2023.

Ten Capital Wealth Advisors reported no remaining ADMA Biologics position as of Q2 2023 after selling out during the quarter.
Ten Capital Wealth Advisors sold 200 ADMA Biologics shares in Q2 2023, an estimated $662.
Ten Capital Wealth Advisors first reported a position in ADMA Biologics in Q1 2022 and held it in 5 quarters.
Ten Capital Wealth Advisors's ADMA Biologics position peaked at $776 in Q4 2022.
179 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2023.

Based on Ten Capital Wealth Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.